https://www.selleckchem.com/pr....oducts/rimiducid-ap1
The optimal treatment for autoimmune type I diabetes mellitus (TIDM) is endogenous regeneration of the pancreatic β-cell. This can be achieved either by transplanting mesenchymal stem cells (BMSCs) from the bone marrow or injecting platelet-rich plasma (PRP). Current research reviewed a TIDM model and compared the effect of BMSCs on exocrine and endocrine pancreas portions versus PRP. Ratsdivided into four groups Control group, Diabetic group (single STZ dose 60 mg / kg I.P), Diabetic + PRP group (PRP, 0.5 ml/kg SC twice weekly
Like
Comment
Share
